{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:32:42Z","timestamp":1794897162574,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID2023-151392OB-I00"],"award-info":[{"award-number":["PID2023-151392OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Gangoiti"},{"DOI":"10.13039\/501100023561","name":"Ministerio de Universidades","doi-asserted-by":"publisher","award":["FPU21\/01545"],"award-info":[{"award-number":["FPU21\/01545"]}],"id":[{"id":"10.13039\/501100023561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023561","name":"Ministerio de Universidades","doi-asserted-by":"publisher","award":["FPU018\/02244"],"award-info":[{"award-number":["FPU018\/02244"]}],"id":[{"id":"10.13039\/501100023561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023561","name":"Ministerio de Universidades","doi-asserted-by":"publisher","award":["FPU19\/03255"],"award-info":[{"award-number":["FPU19\/03255"]}],"id":[{"id":"10.13039\/501100023561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01063"],"award-info":[{"award-number":["PI20\/01063"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01063"],"award-info":[{"award-number":["PI20\/01063"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01063"],"award-info":[{"award-number":["PI20\/01063"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01063"],"award-info":[{"award-number":["PI20\/01063"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PC 192-193"],"award-info":[{"award-number":["PC 192-193"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PC 192-193"],"award-info":[{"award-number":["PC 192-193"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PC 192-193"],"award-info":[{"award-number":["PC 192-193"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["PC 192-193"],"award-info":[{"award-number":["PC 192-193"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01158-x","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:25:17Z","timestamp":1762863917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"11","author":[{"given":"Adriana","family":"Tavira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Basurco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Abellanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Ayerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Vidaurre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Luquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Africa","family":"Vales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gonzalez-Aseguinolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Marrodan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mal\u00fa G\u00e1mez","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Herv\u00e1s-Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Aymerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1158_CR1","doi-asserted-by":"crossref","unstructured":"Burr\u00e9, J., Sharma, M. & S\u00fcdhof, T. C. Cell Biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb. Perspect. Med. 8, a024091 (2018).","DOI":"10.1101\/cshperspect.a024091"},{"key":"1158_CR2","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"1158_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mds.25249","volume":"28","author":"AB Singleton","year":"2013","unstructured":"Singleton, A. B., Farrer, M. J. & Bonifati, V. The genetics of Parkinson\u2019s disease: progress and therapeutic implications. Mov. Disord. 28, 14\u201323 (2013).","journal-title":"Mov. Disord."},{"key":"1158_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","volume":"68","author":"J Fuchs","year":"2007","unstructured":"Fuchs, J. et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68, 916\u2013922 (2007).","journal-title":"Neurology"},{"key":"1158_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1469-1809.2009.00560.x","volume":"74","author":"TL Edwards","year":"2010","unstructured":"Edwards, T. L. et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet. 74, 97\u2013109 (2010).","journal-title":"Ann. Hum. Genet."},{"key":"1158_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/bs.pbr.2019.10.006","volume":"252","author":"AM Schonhoff","year":"2020","unstructured":"Schonhoff, A. M., Williams, G. P., Wallen, Z. D., Standaert, D. G. & Harms, A. S. Innate and adaptive immune responses in Parkinson\u2019s disease. Prog. Brain Res. 252, 169\u2013216 (2020).","journal-title":"Prog. Brain Res."},{"key":"1158_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline, E. M. et al. Genetic and environmental factors in Parkinson\u2019s disease converge on immune function and inflammation. Mov. Disord. 36, 25\u201336 (2021).","journal-title":"Mov. Disord."},{"key":"1158_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/ng.642","volume":"42","author":"TH Hamza","year":"2010","unstructured":"Hamza, T. H. et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson\u2019s disease. Nat. Genet. 42, 781\u2013785 (2010).","journal-title":"Nat. Genet."},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter, I. et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939\u2013946 (2018).","journal-title":"JAMA Neurol."},{"key":"1158_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"X-Y Qin","year":"2016","unstructured":"Qin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P. & Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 73, 1316\u20131324 (2016).","journal-title":"JAMA Neurol."},{"key":"1158_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15626-w","volume":"11","author":"CS Lindestam Arlehamn","year":"2020","unstructured":"Lindestam Arlehamn, C. S. et al. \u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nat. Commun. 11, 1\u201311 (2020).","journal-title":"Nat. Commun."},{"key":"1158_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer, D. et al. T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature 546, 656\u2013661 (2017).","journal-title":"Nature"},{"key":"1158_CR14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology 38, 1285\u20131291 (1988).","journal-title":"Neurology"},{"key":"1158_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","volume":"106","author":"K Imamura","year":"2003","unstructured":"Imamura, K. et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 106, 518\u2013526 (2003).","journal-title":"Acta Neuropathol."},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0304-3940(94)90684-X","volume":"172","author":"G Boka","year":"1994","unstructured":"Boka, G. et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson\u2019s disease. Neurosci. Lett. 172, 151\u2013154 (1994).","journal-title":"Neurosci. Lett."},{"key":"1158_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208\u2013210 (1994).","journal-title":"Neurosci. Lett."},{"key":"1158_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0304-3940(94)90508-8","volume":"180","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Interleukin-1\u03b2, interleukin-6, epidermal growth factor and transforming growth factor-\u03b1 are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147\u2013150 (1994).","journal-title":"Neurosci. Lett."},{"key":"1158_CR19","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard, V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest 119, 182\u2013192 (2009).","journal-title":"J. Clin. Invest"},{"key":"1158_CR20","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira, J., Torra, A., Vila, M. & Bov\u00e9, J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 143, 3717\u20133733 (2020).","journal-title":"Brain"},{"key":"1158_CR21","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/NEN.0b013e31818e5e99","volume":"67","author":"S Theodore","year":"2008","unstructured":"Theodore, S., Cao, S., McLean, P. J. & Standaert, D. G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 1149\u20131158 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1158_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008784","volume":"5","author":"V Sanchez-Guajardo","year":"2010","unstructured":"Sanchez-Guajardo, V., Febbraro, F., Kirik, D. & Romero-Ramos, M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson\u2019s disease. PLoS ONE 5, e8784 (2010).","journal-title":"PLoS ONE"},{"key":"1158_CR23","doi-asserted-by":"publisher","first-page":"15267","DOI":"10.1074\/jbc.M116.714824","volume":"291","author":"G Chandra","year":"2016","unstructured":"Chandra, G., Rangasamy, S. B., Roy, A., Kordower, J. H. & Pahan, K. Neutralization of RANTES and eotaxin prevents the loss of dopaminergic neurons in a mouse model of Parkinson disease. J. Biol. Chem. 291, 15267\u201315281 (2016).","journal-title":"J. Biol. Chem."},{"key":"1158_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40478-017-0494-9","volume":"5","author":"AS Harms","year":"2017","unstructured":"Harms, A. S. et al. \u03b1-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol. Commun. 5, 85 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"1158_CR25","doi-asserted-by":"publisher","first-page":"9592","DOI":"10.1523\/JNEUROSCI.5610-12.2013","volume":"33","author":"AS Harms","year":"2013","unstructured":"Harms, A. S. et al. MHCII is required for \u03b1-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. J. Neurosci. 33, 9592\u20139600 (2013).","journal-title":"J. Neurosci."},{"key":"1158_CR26","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/brain\/awab103","volume":"144","author":"GP Williams","year":"2021","unstructured":"Williams, G. P. et al. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Brain 144, 2047\u20132059 (2021).","journal-title":"Brain"},{"key":"1158_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/glia.24295","volume":"71","author":"L Basurco","year":"2023","unstructured":"Basurco, L. et al. Microglia and astrocyte activation is region-dependent in the \u03b1-synuclein mouse model of Parkinson\u2019s disease. Glia 71, 571\u2013587 (2023).","journal-title":"Glia"},{"key":"1158_CR28","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMct1101691","volume":"366","author":"D Pelletier","year":"2012","unstructured":"Pelletier, D. & Hafler, D. A. Fingolimod for multiple sclerosis. N. Engl. J. Med. 366, 339\u2013347 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O","volume":"30","author":"H Yagi","year":"2000","unstructured":"Yagi, H. et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur. J. Immunol. 30, 1435\u20131444 (2000).","journal-title":"Eur. J. Immunol."},{"key":"1158_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1096\/fj.201600751r","volume":"31","author":"P Zhao","year":"2017","unstructured":"Zhao, P. et al. Neuroprotective effects of fingolimod in mouse models of Parkinson\u2019s disease. FASEB J. 31, 172\u2013179 (2017).","journal-title":"FASEB J."},{"key":"1158_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1326-8-44","volume":"8","author":"M Oliveras-Salv\u00e1","year":"2013","unstructured":"Oliveras-Salv\u00e1, M. et al. rAAV2\/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol. Neurodegener. 8, 44 (2013).","journal-title":"Mol. Neurodegener."},{"key":"1158_CR32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1126\/science.1081297","volume":"301","author":"PM Steed","year":"2003","unstructured":"Steed, P. M. et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301, 1895\u20131898 (2003).","journal-title":"Science"},{"key":"1158_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JPD-140410","volume":"4","author":"CJ Barnum","year":"2014","unstructured":"Barnum, C. J. et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro\u00ae1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J. Parkinsons Dis. 4, 349\u2013360 (2014).","journal-title":"J. Parkinsons Dis."},{"key":"1158_CR34","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/brain\/awr203","volume":"134","author":"E Taoufik","year":"2011","unstructured":"Taoufik, E. et al. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain 134, 2722\u20132735 (2011).","journal-title":"Brain"},{"key":"1158_CR35","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1093\/brain\/awr199","volume":"134","author":"R Brambilla","year":"2011","unstructured":"Brambilla, R. et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 134, 2736\u20132754 (2011).","journal-title":"Brain"},{"key":"1158_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","volume":"1382","author":"MJ Castle","year":"2016","unstructured":"Castle, M. J., Turunen, H. T., Vandenberghe, L. H. & Wolfe, J. H. Controlling AAV tropism in the nervous system with natural and engineered capsids. Methods Mol. Biol. 1382, 133\u2013149 (2016).","journal-title":"Methods Mol. Biol."},{"key":"1158_CR37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","volume":"13","author":"CN Cearley","year":"2006","unstructured":"Cearley, C. N. & Wolfe, J. H. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol. Ther. 13, 528\u2013537 (2006).","journal-title":"Mol. Ther."},{"key":"1158_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41531-022-00438-0","volume":"8","author":"D Mamula","year":"2022","unstructured":"Mamula, D., Khosousi, S., He, Y., Lazarevic, V. & Svenningsson, P. Impaired migratory phenotype of CD4+ T cells in Parkinson\u2019s disease. npj Parkinsons Dis. 8, 171 (2022).","journal-title":"npj Parkinsons Dis."},{"key":"1158_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00018-024-05402-0","volume":"81","author":"X Sun","year":"2024","unstructured":"Sun, X., Gu, R. & Bai, J. Differentiation and regulation of CD4+ T cell subsets in Parkinson\u2019s disease. Cell. Mol. Life Sci. 81, 352 (2024).","journal-title":"Cell. Mol. Life Sci."},{"key":"1158_CR40","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883\u2013897 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1158_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03091-x","volume":"21","author":"L Ayerra","year":"2024","unstructured":"Ayerra, L. et al. Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity. J. Neuroinflammation 21, 92 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1158_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fphar.2020.00077","volume":"11","author":"\u00c9 P\u00e9pin","year":"2020","unstructured":"P\u00e9pin, \u00c9, Jalinier, T., Lemieux, G. L., Massicotte, G. & Cyr, M. Sphingosine-1-phosphate receptors modulators decrease signs of neuroinflammation and prevent Parkinson\u2019s disease symptoms in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model. Front. Pharmacol. 11, 77 (2020).","journal-title":"Front. Pharmacol."},{"key":"1158_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/jnc.14575","volume":"147","author":"D Komnig","year":"2018","unstructured":"Komnig, D. et al. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson\u2019s disease and does not lead to a sustainable increase of brain-derived neurotrophic factor. J. Neurochem. 147, 678\u2013691 (2018).","journal-title":"J. Neurochem."},{"key":"1158_CR44","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nn.3728","volume":"17","author":"NC Hait","year":"2014","unstructured":"Hait, N. C. et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat. Neurosci. 17, 971\u2013980 (2014).","journal-title":"Nat. Neurosci."},{"key":"1158_CR45","doi-asserted-by":"publisher","first-page":"14230","DOI":"10.1073\/pnas.1206093109","volume":"109","author":"R Deogracias","year":"2012","unstructured":"Deogracias, R. et al. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. USA 109, 14230\u201314235 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1158_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107701","volume":"158","author":"J Vargas-Medrano","year":"2019","unstructured":"Vargas-Medrano, J. et al. FTY720-Mitoxy reduces toxicity associated with MSA-like \u03b1-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures. Neuropharmacology 158, 107701 (2019).","journal-title":"Neuropharmacology"},{"key":"1158_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jphs.2017.02.006","volume":"133","author":"I Segura-Ulate","year":"2017","unstructured":"Segura-Ulate, I., Belcher, T. K., Vidal-Martinez, G., Vargas-Medrano, J. & Perez, R. G. FTY720-derivatives do not induce FTY720-like lymphopenia. J. Pharm. Sci. 133, 187\u2013189 (2017).","journal-title":"J. Pharm. Sci."},{"key":"1158_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1124\/mol.105.020552","volume":"70","author":"SW Paugh","year":"2006","unstructured":"Paugh, S. W. et al. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor. Mol. Pharm. 70, 41\u201350 (2006).","journal-title":"Mol. Pharm."},{"key":"1158_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.brainres.2005.12.014","volume":"1073\u20131074","author":"S Gonz\u00e1lez","year":"2006","unstructured":"Gonz\u00e1lez, S. et al. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson\u2019s disease. Brain Res. 1073\u20131074, 209\u2013219 (2006).","journal-title":"Brain Res."},{"key":"1158_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.nbd.2004.10.015","volume":"18","author":"E Fernandez-Espejo","year":"2005","unstructured":"Fernandez-Espejo, E. et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18, 591\u2013601 (2005).","journal-title":"Neurobiol. Dis."},{"key":"1158_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0304-3940(97)00850-1","volume":"238","author":"L Aloe","year":"1997","unstructured":"Aloe, L. & Fiore, M. TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci. Lett. 238, 65\u201368 (1997).","journal-title":"Neurosci. Lett."},{"key":"1158_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/mt.2010.217","volume":"19","author":"AS Harms","year":"2011","unstructured":"Harms, A. S. et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson\u2019s disease. Mol. Ther. 19, 46\u201352 (2011).","journal-title":"Mol. Ther."},{"key":"1158_CR53","doi-asserted-by":"crossref","unstructured":"Christiansen, J. R. et al. Peripherally administered TNF inhibitor is not protective against \u03b1-synuclein-induced dopaminergic neuronal death in rats. Neurobiol. Dis. 206, 106803 (2025).","DOI":"10.1016\/j.nbd.2025.106803"},{"key":"1158_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02200-4","volume":"18","author":"I Papazian","year":"2021","unstructured":"Papazian, I. et al. Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKK\u03b2 promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice. J. Neuroinflammation 18, 222 (2021).","journal-title":"J. Neuroinflammation"},{"key":"1158_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.19","volume":"5","author":"S D\u2019Costa","year":"2016","unstructured":"D\u2019Costa, S. et al. Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR. Mol. Ther. Methods Clin. Dev. 5, 16019 (2016).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1158_CR56","unstructured":"Paxinos, G. & Franklin, K. B. J. The Mouse Brain in Sterotaxic Coordinates (Academic Press, 2001)."},{"key":"1158_CR57","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2818.1987.tb02837.x","volume":"147","author":"HJG Gundersen","year":"1987","unstructured":"Gundersen, H. J. G. & Jensen, E. B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147, 229\u2013263 (1987).","journal-title":"J. Microsc."},{"key":"1158_CR58","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cyto.a.22021","volume":"81","author":"W-S Juan","year":"2012","unstructured":"Juan, W.-S. et al. Optimal Percoll concentration facilitates flow cytometric analysis for annexin V\/propidium iodine-stained ischemic brain tissues. Cytom. A 81, 400\u2013408 (2012).","journal-title":"Cytom. A"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01158-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:05:24Z","timestamp":1762869924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01158-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01158-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6252707\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.G.T. has patent #US 11,365,229 B2 \u201cMethods of treating neurological diseases,\u201d issued to XENCOR, INC, Monrovia, CA (US). M.G.T. has patent #US7,144,987 B1 issued to Xencor, Inc., Monrovia, CA. M.G.T. has patent #US7,244,823 B2 issued to Xencor, Inc., Monrovia, CA. M.G.T. is an ex-employee of Xencor Inc., where she co-invented the DN-TNFs. She is a consultant to INmune Bio, which licensed XPro1595 for neurological indications and holds stock in the company. M.G.T. is Editor-in-Chief of\n                      npj Parkinson\u2019s disease\n                      . The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}